Compare StocksCME vs JNJ

CME Group Inc. (CME) vs Johnson & Johnson (JNJ): Which Is the Better Buy in 2026?

As of 2026-06-19, CME is overvalued at $246, with a DCF intrinsic value of $218 and a margin of safety of -13%. JNJ is fairly valued at $228, with an intrinsic value of $281 and a margin of safety of 19%. Of the two, JNJ has the wider margin of safety.

CME
CME Group Inc.
$246.38
VS
JNJ
Johnson & Johnson
$228.39

Rewards

CME
  • Gross margin of 100.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • CME Group Inc. scores 77/100 on the Economic Moat Score (Wide Moat), with margin stability as the strongest competitive dimension.
  • Free cash flow has grown at a 12.2% CAGR over the past 4 years, demonstrating strong earnings power growth.
JNJ
  • Johnson & Johnson has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • Gross margin of 68.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Johnson & Johnson scores 90/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.

Risks

CME
  • PEG ratio of 4.59 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
  • Altman Z-Score of 0.53 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
JNJ
  • Trailing P/E of 26.5x is 33% above the historical average of 20.0x — the stock trades at a premium to its own history.
  • PEG ratio of 3.06 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
  • Insiders have sold $2.4M worth of stock in the past 3 months — significant insider liquidation.

Key Valuation Metrics

Learn more →
CME
JNJ
Valuation
$4.19B
Free Cash Flow
$19.31B
4.71%
FCF Yield
3.51%
21.41
Trailing P/E
26.46
19.07
Forward P/E
17.96
Quality & Moat
12.25%
ROIC
15.32%
15.92%
ROE
26.42%
100.00%
Gross Margin
68.04%
4.59
PEG Ratio
3.06
Balance Sheet Safety
0.05
Net Debt / Equity
0.41
N/A
Interest Coverage
N/A
0.26
Net Debt / EBITDA
0.96
1.99%
Dividend Yield
2.22%
CME: 5Ties: 1JNJ: 6
CMEJNJ

Historical Fundamentals

Learn more →
CME

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

JNJ

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
CME
$526.78
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$71.5M
Δ Market Cap
+$37.66B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
JNJ
$0.91
created per $1 retained over 3 years
Mediocre Allocator
Σ Retained
$40.05B
Δ Market Cap
+$36.63B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
CME
12.9% Overvalued
Price is 12.9% above estimated fair value
Current Price: $246.38
Fair Value: $218.17
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
JNJ
18.6% Margin of Safety
Price is 18.6% below estimated fair value
Current Price: $228.39
Fair Value: $280.51
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
CME

What growth rate is the market pricing in at $246?

+8.3%
Market-Implied Owner Earnings Growth
Standard FCF implies +8.7%

The market implies +8.3% Owner Earnings growth, below historical trends — potential opportunity.

Standard FCF implies a more demanding +8.7%, reflecting heavy growth investment expected to generate future returns.

JNJ

What growth rate is the market pricing in at $228?

+7.7%
Market-Implied Owner Earnings Growth
Standard FCF implies +13.3%

The market implies +7.7% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +13.3%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
CME
77/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat driven primarily by margin stability. ROIC Consistency is the area most vulnerable to competitive pressure.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
JNJ
90/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

Forensic Accounting

Learn more →
CME
-2.43
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
JNJ
-2.31
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
CME
Insiders 0.4%Institutions 92.7%Retail & Other 6.9%
No. of Institutional Holders2,391
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
JNJ
Insiders 0.1%Institutions 76.9%Retail & Other 23.1%
No. of Institutional Holders5,728
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
CME
1
Buys (3M)
2
Buys (12M)
Total value (12M): $509,437
SHEPARD WILLIAM R
Director
$437,101
@ $297.55 · 2026-03-26
SHEPARD WILLIAM R
Director
$72,336
@ $270.92 · 2025-06-25
SHEPARD WILLIAM R
Director
$71,995
@ $262.76 · 2025-03-26
SHEPARD WILLIAM R
Director
$325,798
@ $227.99 · 2025-01-16
SHEPARD WILLIAM R
Director
$324,198
@ $227.99 · 2025-01-16
BENESH KATHRYN
Director
$3,595
@ $239.67 · 2024-12-27
SHEPARD WILLIAM R
Director
$63,945
@ $218.99 · 2024-09-25
Open market purchases · includes direct & indirect ownership · excludes option exercises
JNJ
0
Buys (3M)
1
Buys (12M)
Total value (12M): $257,688
MORIKIS JOHN G
Director
$257,688
@ $206.15 · 2025-11-26
WEINBERGER MARK A
Director
$147,220
@ $147.22 · 2024-12-12
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
CME
2
Sells (3M)
14
Sells (12M)
Total value (12M): $28.07M
PIELL HILDA HARRIS
Officer
$1.75M
@ $304.63 · 2026-05-18
DUFFY TERRENCE A
Chief Executive Officer
$10.45M
@ $298.51 · 2026-05-15
MARCUS JONATHAN L
General Counsel
$1.10M
@ $333.37 · 2026-03-17
MARCUS JONATHAN L
Officer
$1.03M
@ $313.37 · 2026-03-17
VROMAN KENDAL L
Officer
$1.59M
@ $309.00 · 2026-03-12
DURKIN BRYAN T
Director
$1.30M
@ $309.65 · 2026-02-23
GEPSMAN MARTIN J
Director
$91,770
@ $305.90 · 2026-02-20
SUSKIND DENNIS A
Director
$224,400
@ $300.00 · 2026-02-06
DUFFY TERRENCE A
Chief Executive Officer
$6.74M
@ $269.55 · 2025-12-11
FORD HAROLD EUGENE JR
Director
$263,530
@ $263.53 · 2025-11-03
MARCUS JONATHAN L
General Counsel
$102,704
@ $262.00 · 2025-09-18
MCCOURT TIMOTHY FRANCIS
Officer
$98,476
@ $259.83 · 2025-09-16
MARCUS JONATHAN L
General Counsel
$97,369
@ $258.96 · 2025-09-16
CUTINHO SUNIL KIRAN
Chief Technology Officer
$3.23M
@ $271.47 · 2025-08-26
KAYE DANIEL G
Director
$141,210
@ $282.42 · 2025-05-22
MARCUS JONATHAN L
General Counsel
$108,225
@ $277.50 · 2025-05-20
LOCKETT PHYLLIS M
Director
$294,553
@ $277.88 · 2025-05-19
GEPSMAN MARTIN J
Director
$81,951
@ $273.17 · 2025-05-15
SUSKIND DENNIS A
Director
$271,280
@ $271.28 · 2025-04-29
GERDES LARRY G
Director
$1.06M
@ $265.11 · 2025-04-25
LUCAS DEBORAH J
Director
$385,425
@ $256.95 · 2025-03-14
DUFFY TERRENCE A
Chief Executive Officer
$7.78M
@ $259.18 · 2025-03-11
SPRAGUE SUZANNE
Chief Operating Officer
$385,249
@ $256.83 · 2025-03-03
PIELL HILDA HARRIS
Officer
$997,853
@ $250.47 · 2025-02-27
WINKLER JULIE
Officer
$2.89M
@ $249.17 · 2025-02-13
VROMAN KENDAL L
Officer
$1.27M
@ $250.00 · 2025-02-13
GEPSMAN MARTIN J
Director
$89,168
@ $222.92 · 2024-11-04
CUTINHO SUNIL KIRAN
Chief Technology Officer
$1.02M
@ $226.64 · 2024-10-30
BITSBERGER TIMOTHY S
Director
$226,957
@ $226.96 · 2024-10-30
MCCOURT TIMOTHY FRANCIS
Officer
$312,056
@ $227.11 · 2024-10-28
FITZPATRICK LYNNE
Chief Financial Officer
$163,610
@ $216.99 · 2024-09-13
DURKIN BRYAN T
Director
$1.63M
@ $214.59 · 2024-08-30
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
JNJ
1
Sells (3M)
13
Sells (12M)
Total value (12M): $103.65M
WENGEL KATHRYN E
Chief Technology Officer
$2.41M
@ $241.15 · 2026-06-11
DECKER ROBERT J
Officer
$1.01M
@ $247.87 · 2026-02-27
SCHMID TIMOTHY
Officer
$324,763
@ $245.66 · 2026-02-20
SCHMID TIMOTHY
Officer
$5.53M
@ $244.33 · 2026-02-18
SWANSON JAMES D
Chief Technology Officer
$15.11M
@ $243.39 · 2026-02-17
BROADHURST VANESSA
Officer
$1.51M
@ $243.39 · 2026-02-17
WOLK JOSEPH J
Chief Financial Officer
$21.77M
@ $242.80 · 2026-02-17
REED JOHN C
Officer
$13.11M
@ $243.00 · 2026-02-17
REED JOHN C
Officer
$4.19M
@ $192.71 · 2025-10-17
TAUBERT JENNIFER L
Officer
$10.04M
@ $177.81 · 2025-09-04
DUATO JOAQUIN BOIX
Chief Executive Officer
$22.55M
@ $179.21 · 2025-08-22
WOLK JOSEPH J
Chief Financial Officer
$2.98M
@ $176.91 · 2025-08-15
REED JOHN C
Officer
$3.13M
@ $163.55 · 2025-07-17
DECKER ROBERT J
Officer
$1.16M
@ $165.88 · 2025-02-25
SCHMID TIMOTHY
Officer
$62,928
@ $156.15 · 2025-02-18
WOLK JOSEPH J
Chief Financial Officer
$2.00M
@ $153.89 · 2025-02-07
DECKER ROBERT J
Officer
$930,113
@ $165.06 · 2024-08-30
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
CME
FearGreed
😨Fear(32/100)

"Market is pessimistic — investigate whether fears are temporary or structural"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
JNJ
FearGreed
😏Greed(62/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
CME
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Fear (32)
JNJ
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (62)
View CME Full AnalysisView JNJ Full Analysis

Frequently Asked Questions: CME vs JNJ

Is CME Group Inc. or Johnson & Johnson more undervalued in 2026?

Based on our discounted cash flow model, JNJ trades at a 18.6% margin of safety (intrinsic value $281 vs. price $228), compared to CME's -12.9% margin of safety (intrinsic $218 vs. $246).

Which stock has a wider economic moat, CME Group Inc. or Johnson & Johnson?

JNJ scores 90/100 (Wide moat), while CME scores 77/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is CME Group Inc. in financial distress?

CME's Altman Z-Score of 0.5 places it in the Distress zone, signaling elevated bankruptcy risk. JNJ scores 3.5 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which company has better free cash flow, CME Group Inc. or Johnson & Johnson?

CME Group Inc. (CME) generates a 4.7% free cash flow yield, compared to Johnson & Johnson's 3.5%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, CME Group Inc. or Johnson & Johnson?

JNJ earns 15.3% ROIC versus CME's 12.2%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, CME Group Inc.'s or Johnson & Johnson's?

JNJ's dividend earns a safety score of 79/100 (Safe), compared to CME's 34/100 (Unsafe). JNJ has raised its dividend for 3 consecutive years.